Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

[Reuters] – An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc’s blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by . . . → Read More: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Third-Quarter 2014 Dividend Market Update (NYSE:LLY): Lilly Declares Second-Quarter 2014 Dividend Stock Update (NYSE:LLY): U.S. FDA approves Eli Lilly drug for stomach cancer